CA2645053A1 - Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines - Google Patents
Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines Download PDFInfo
- Publication number
- CA2645053A1 CA2645053A1 CA002645053A CA2645053A CA2645053A1 CA 2645053 A1 CA2645053 A1 CA 2645053A1 CA 002645053 A CA002645053 A CA 002645053A CA 2645053 A CA2645053 A CA 2645053A CA 2645053 A1 CA2645053 A1 CA 2645053A1
- Authority
- CA
- Canada
- Prior art keywords
- integer
- cooh
- amino
- alkanoyloxy
- configuration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 57
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 43
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 20
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 17
- 201000010099 disease Diseases 0.000 title claims abstract description 14
- 230000002519 immonomodulatory effect Effects 0.000 title claims abstract description 10
- 238000012261 overproduction Methods 0.000 title claims abstract description 9
- 238000011282 treatment Methods 0.000 title abstract description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 49
- 208000006673 asthma Diseases 0.000 claims abstract description 46
- -1 dihydroxyphosphoryloxy Chemical group 0.000 claims abstract description 42
- 125000004423 acyloxy group Chemical group 0.000 claims abstract description 41
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 41
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 23
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 12
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 6
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract description 6
- 125000002252 acyl group Chemical group 0.000 claims abstract description 6
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 6
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 6
- 206010003246 arthritis Diseases 0.000 claims abstract description 5
- 201000007094 prostatitis Diseases 0.000 claims abstract description 5
- 125000004442 acylamino group Chemical group 0.000 claims abstract description 3
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract description 3
- 125000001424 substituent group Chemical group 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 33
- 241001465754 Metazoa Species 0.000 claims description 32
- 108090000978 Interleukin-4 Proteins 0.000 claims description 30
- 108090000176 Interleukin-13 Proteins 0.000 claims description 24
- 239000000443 aerosol Substances 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 15
- 108010002616 Interleukin-5 Proteins 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 238000007920 subcutaneous administration Methods 0.000 claims description 7
- DUVFGVANBUHUNU-GBYUNDSOSA-N [(3r)-1-[[(2s)-4-hydroxy-1-[[(4r)-5-hydroxy-4-[[(3r)-3-hydroxytetradecanoyl]amino]pentyl]amino]-1-oxobutan-2-yl]amino]-1-oxotetradecan-3-yl] dodecanoate Chemical compound CCCCCCCCCCC[C@@H](O)CC(=O)N[C@@H](CO)CCCNC(=O)[C@H](CCO)NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC DUVFGVANBUHUNU-GBYUNDSOSA-N 0.000 claims description 6
- 229960005261 aspartic acid Drugs 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 125000001589 carboacyl group Chemical group 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 5
- 229920001577 copolymer Chemical group 0.000 claims description 5
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 4
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 108010002335 Interleukin-9 Proteins 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- RWKSHMIMEZGXJM-ZGIXZKLDSA-N [(3R)-1-[[(2S)-6-amino-1-[[(4R)-5-hydroxy-4-[[(3R)-3-hydroxytetradecanoyl]amino]pentyl]amino]-1-oxohexan-2-yl]amino]-1-oxotetradecan-3-yl] dodecanoate Chemical compound CCCCCCCCCCC[C@@H](O)CC(=O)N[C@@H](CO)CCCNC(=O)[C@H](CCCCN)NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC RWKSHMIMEZGXJM-ZGIXZKLDSA-N 0.000 claims 1
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 137
- 239000000243 solution Substances 0.000 description 55
- 210000004072 lung Anatomy 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 35
- 102000004388 Interleukin-4 Human genes 0.000 description 29
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- 210000003979 eosinophil Anatomy 0.000 description 23
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
- 239000002158 endotoxin Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 229920006008 lipopolysaccharide Polymers 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- 210000004443 dendritic cell Anatomy 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 14
- 230000010085 airway hyperresponsiveness Effects 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 238000003818 flash chromatography Methods 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 235000019341 magnesium sulphate Nutrition 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 241001529936 Murinae Species 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- 229910052786 argon Inorganic materials 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- ZYHGAWNKVNFJDL-UHFFFAOYSA-N 8-methylnon-7-enoic acid Chemical compound CC(C)=CCCCCCC(O)=O ZYHGAWNKVNFJDL-UHFFFAOYSA-N 0.000 description 8
- 108090000174 Interleukin-10 Proteins 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229960002329 methacholine Drugs 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 7
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- 206010014950 Eosinophilia Diseases 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- HDFFVHSMHLDSLO-UHFFFAOYSA-M dibenzyl phosphate Chemical compound C=1C=CC=CC=1COP(=O)([O-])OCC1=CC=CC=C1 HDFFVHSMHLDSLO-UHFFFAOYSA-M 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 208000037884 allergic airway inflammation Diseases 0.000 description 4
- 201000009961 allergic asthma Diseases 0.000 description 4
- 229940037003 alum Drugs 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 210000005007 innate immune system Anatomy 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 229920001992 poloxamer 407 Polymers 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 235000019345 sodium thiosulphate Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 3
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- IUWHMFHZPLBCPO-UHFFFAOYSA-N 5-(oxiran-2-yl)pentanoic acid Chemical compound OC(=O)CCCCC1CO1 IUWHMFHZPLBCPO-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- NFAWDMFMQIKANO-UHFFFAOYSA-N benzyl hept-6-enoate Chemical compound C=CCCCCC(=O)OCC1=CC=CC=C1 NFAWDMFMQIKANO-UHFFFAOYSA-N 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000002510 pyrogen Substances 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 150000003536 tetrazoles Chemical class 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- IKRFTYQBIVDIMM-XMMPIXPASA-N (3r)-3-dodecanoyloxytetradecanoic acid Chemical compound CCCCCCCCCCC[C@H](CC(O)=O)OC(=O)CCCCCCCCCCC IKRFTYQBIVDIMM-XMMPIXPASA-N 0.000 description 2
- IGPABHSEKYCFIS-JWQCQUIFSA-N (3r)-n-[(2r)-5-amino-1-hydroxypentan-2-yl]-3-phenylmethoxytetradecanamide Chemical compound CCCCCCCCCCC[C@H](CC(=O)N[C@@H](CO)CCCN)OCC1=CC=CC=C1 IGPABHSEKYCFIS-JWQCQUIFSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000239218 Limulus Species 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 230000007689 endotoxicity Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000035780 glucosuria Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000031261 interleukin-10 production Effects 0.000 description 2
- 230000019734 interleukin-12 production Effects 0.000 description 2
- 230000018711 interleukin-13 production Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000013586 microbial product Substances 0.000 description 2
- NLGUJOVLAXLSMX-UHFFFAOYSA-N n-bis(phenylmethoxy)phosphanyl-n-ethylethanamine Chemical compound C=1C=CC=CC=1COP(N(CC)CC)OCC1=CC=CC=C1 NLGUJOVLAXLSMX-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229940044476 poloxamer 407 Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 210000004986 primary T-cell Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- FLYIRERUSAMCDQ-UHFFFAOYSA-N 2-azaniumyl-2-(2-methylphenyl)acetate Chemical compound CC1=CC=CC=C1C(N)C(O)=O FLYIRERUSAMCDQ-UHFFFAOYSA-N 0.000 description 1
- RXQDBVWDABAAHL-UHFFFAOYSA-N 6-(phenylmethoxycarbonylamino)hexanoic acid Chemical compound OC(=O)CCCCCNC(=O)OCC1=CC=CC=C1 RXQDBVWDABAAHL-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 102000002791 Interleukin-8B Receptors Human genes 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 238000011050 LAL assay Methods 0.000 description 1
- 241000222732 Leishmania major Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- MKLNTBLOABOJFZ-DFWYDOINSA-N [(3s)-2-oxooxolan-3-yl]azanium;bromide Chemical compound Br.N[C@H]1CCOC1=O MKLNTBLOABOJFZ-DFWYDOINSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029771 childhood onset asthma Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 108010072542 endotoxin binding proteins Proteins 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB2006/050748 | 2006-03-09 | ||
| IBPCT/IB2006/050748 | 2006-03-09 | ||
| PCT/IB2007/000567 WO2007102081A2 (en) | 2006-03-09 | 2007-03-09 | Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2645053A1 true CA2645053A1 (en) | 2007-09-13 |
Family
ID=38475231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002645053A Abandoned CA2645053A1 (en) | 2006-03-09 | 2007-03-09 | Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7915240B2 (enExample) |
| EP (1) | EP2051728A4 (enExample) |
| JP (1) | JP5341526B2 (enExample) |
| KR (1) | KR20080105048A (enExample) |
| CN (1) | CN101511379A (enExample) |
| AU (1) | AU2007222135B2 (enExample) |
| BR (1) | BRPI0708363A2 (enExample) |
| CA (1) | CA2645053A1 (enExample) |
| IL (1) | IL192837A (enExample) |
| MX (1) | MX2008011360A (enExample) |
| NO (1) | NO20084195L (enExample) |
| RU (1) | RU2498813C2 (enExample) |
| WO (1) | WO2007102081A2 (enExample) |
| ZA (1) | ZA200806266B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2645053A1 (en) * | 2006-03-09 | 2007-09-13 | Om Pharma | Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines |
| KR101108161B1 (ko) | 2009-12-24 | 2012-01-31 | 삼성모바일디스플레이주식회사 | 유기 발광 표시 장치 및 그 제조방법 |
| US10065978B2 (en) | 2015-11-24 | 2018-09-04 | University Of South Carolina | Cysteine-modifying substrate analogue inhibitors of ribose 5-phosphate isomerase for parasitic diseases, along with methods of their formation and use |
| US10682359B2 (en) | 2017-03-31 | 2020-06-16 | University Of South Carolina | Inhibitors of glucose kinases, along with methods of their formation and use |
| US11059842B2 (en) | 2019-04-29 | 2021-07-13 | University Of South Carolina | Monosaccharide amine and 3-nitro-2-phenyl-2H-chromene based inhibitors of glucose kinases |
| US11555047B2 (en) | 2019-10-31 | 2023-01-17 | University Of South Carolina | One-step synthesis of phosphate-based inhibitors and applications thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT879056E (pt) * | 1996-01-23 | 2002-10-31 | Ribapharm Inc | Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados |
| JP4305662B2 (ja) * | 1996-09-30 | 2009-07-29 | 大塚製薬株式会社 | サイトカイン産生抑制剤及び接着抑制剤 |
| AU738170B2 (en) * | 1996-10-16 | 2001-09-13 | Icn Pharmaceuticals, Inc. | Monocyclic L-nucleosides, analogs and uses thereof |
| KR20010021789A (ko) | 1997-08-04 | 2001-03-15 | 야스이 쇼사꾸 | 촉매 및 방향족 카보네이트의 제조방법 |
| IT1296985B1 (it) * | 1997-12-19 | 1999-08-03 | Zambon Spa | Derivati benzazinici inibitori della fosfodiesterasi 4 |
| CA2332946A1 (en) | 1998-05-22 | 1999-12-02 | Welfide Corporation | Hydroxamic acid derivative and pharmaceutical use thereof |
| US7157092B1 (en) * | 1998-06-30 | 2007-01-02 | Om Pharma | Acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same |
| US6831069B2 (en) | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| AU1581400A (en) * | 1999-12-22 | 2001-07-03 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
| AU2001234582A1 (en) * | 2000-01-25 | 2001-08-14 | Nuvelo, Inc. | Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides |
| JP2001316260A (ja) * | 2000-02-29 | 2001-11-13 | Meiji Milk Prod Co Ltd | カバラクトン類を有効成分とするＴＮＦ−α産生抑制剤 |
| DE20220947U1 (de) * | 2001-02-28 | 2004-09-30 | Ribapharm, Inc., Costa Mesa | Pyrrolo2,3-dpyrimidin-Nucleosidanaloga |
| RU2190422C1 (ru) * | 2001-04-25 | 2002-10-10 | Кожемякин Леонид Андреевич | Аэрозоль для ингаляций фармацевтической композиции глутовент и способ лечения с его использованием |
| JP4902913B2 (ja) * | 2001-07-11 | 2012-03-21 | 森下仁丹株式会社 | ＴＮＦ−α産生抑制剤 |
| JP2004107220A (ja) * | 2002-09-13 | 2004-04-08 | Mitsubishi Pharma Corp | ＴＮＦ−α産生抑制剤 |
| JP2004256403A (ja) * | 2003-02-25 | 2004-09-16 | Kyowa Hakko Kogyo Co Ltd | ＴＮＦ−α産生抑制剤 |
| EP1602655A4 (en) * | 2003-03-07 | 2010-06-09 | Kowa Co | benzofuran |
| CA2645053A1 (en) | 2006-03-09 | 2007-09-13 | Om Pharma | Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines |
-
2007
- 2007-03-09 CA CA002645053A patent/CA2645053A1/en not_active Abandoned
- 2007-03-09 AU AU2007222135A patent/AU2007222135B2/en not_active Ceased
- 2007-03-09 EP EP07733936A patent/EP2051728A4/en not_active Withdrawn
- 2007-03-09 JP JP2008557846A patent/JP5341526B2/ja not_active Expired - Fee Related
- 2007-03-09 WO PCT/IB2007/000567 patent/WO2007102081A2/en not_active Ceased
- 2007-03-09 ZA ZA200806266A patent/ZA200806266B/xx unknown
- 2007-03-09 BR BRPI0708363-7A patent/BRPI0708363A2/pt not_active IP Right Cessation
- 2007-03-09 CN CNA2007800075716A patent/CN101511379A/zh active Pending
- 2007-03-09 RU RU2008139985/15A patent/RU2498813C2/ru not_active IP Right Cessation
- 2007-03-09 US US12/279,845 patent/US7915240B2/en not_active Expired - Fee Related
- 2007-03-09 KR KR1020087020919A patent/KR20080105048A/ko not_active Ceased
- 2007-03-09 MX MX2008011360A patent/MX2008011360A/es active IP Right Grant
-
2008
- 2008-07-16 IL IL192837A patent/IL192837A/en not_active IP Right Cessation
- 2008-10-07 NO NO20084195A patent/NO20084195L/no not_active Application Discontinuation
-
2011
- 2011-03-28 US US13/073,737 patent/US8618080B2/en not_active Expired - Fee Related
-
2013
- 2013-11-27 US US14/092,589 patent/US20140086960A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007222135A1 (en) | 2007-09-13 |
| RU2008139985A (ru) | 2010-04-20 |
| WO2007102081A3 (en) | 2009-04-23 |
| WO2007102081A2 (en) | 2007-09-13 |
| AU2007222135B2 (en) | 2012-02-02 |
| BRPI0708363A2 (pt) | 2011-05-24 |
| JP2009529523A (ja) | 2009-08-20 |
| US20140086960A1 (en) | 2014-03-27 |
| NO20084195L (no) | 2008-10-07 |
| RU2498813C2 (ru) | 2013-11-20 |
| JP5341526B2 (ja) | 2013-11-13 |
| US7915240B2 (en) | 2011-03-29 |
| KR20080105048A (ko) | 2008-12-03 |
| IL192837A (en) | 2013-12-31 |
| US20090054378A1 (en) | 2009-02-26 |
| CN101511379A (zh) | 2009-08-19 |
| US20120178721A1 (en) | 2012-07-12 |
| EP2051728A2 (en) | 2009-04-29 |
| EP2051728A4 (en) | 2010-03-31 |
| ZA200806266B (en) | 2010-05-26 |
| MX2008011360A (es) | 2009-03-03 |
| US8618080B2 (en) | 2013-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102809631B1 (ko) | 융합된-바이사이클릭 C5aR 길항제의 프로드러그 | |
| US10941115B2 (en) | Kinase inhibitors | |
| JP6764396B2 (ja) | 二糖合成脂質化合物およびその使用 | |
| AU2017273771B2 (en) | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases | |
| CA2337807C (fr) | Nouveaux pseudodipeptides acyles, leur mode de preparation et les compositions pharmaceutiques en renfermant | |
| AU707779B2 (en) | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | |
| US8618080B2 (en) | Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines | |
| KR20150073942A (ko) | 유기 화합물 | |
| EP3880668B1 (en) | Pyridin-sulfonamide compounds for the treatment of conditions related to interleukin 1 beta | |
| KR20260046445A (ko) | 이미다조[4,5-d]피리다진 화합물 및 이의 접합체, 이의 제조 및 이의 치료적 적용 | |
| AU2012202597A1 (en) | Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines | |
| RU2803242C2 (ru) | Соединения пиридинсульфонамида для лечения состояний, связанных с интерлейкином 1 бета | |
| US12115161B2 (en) | Prophylactic and/or therapeutic agent for inflammatory diseases which contains pyrrolopyrimidine compound as active ingredient | |
| RU2794327C2 (ru) | ПРОЛЕКАРСТВА СОПРЯЖЕННО-БИЦИКЛИЧЕСКИХ АНТАГОНИСТОВ C5aR | |
| EA043820B1 (ru) | Лиганды toll-подобных рецепторов | |
| BR112018074919B1 (pt) | Uso de indazóis 2-substituídos para preparação de medicamento para tratamento e profilaxia de doenças autoimunes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20150310 |